Search

Your search keyword '"Reuss, Annicka"' showing total 8 results
Start Over Author "Reuss, Annicka" Topic 610 medizin und gesundheit
8 results on '"Reuss, Annicka"'

1. COVID-19 bei einer Großveranstaltung: Erfahrungen aus der Kieler Woche 2022

Author

Fickenscher, Helmut, Rose, Ruben, Voß, Mathias, Gorin, Alexey, Maschkowitz, Gregor, Christiansen, Bärbel, Hering, Annika, Stieper, Silvia, Weigl, Josef, Liesche, Tizia, Marcic, Anne, and Reuß, Annicka

Subjects
SARS-CoV-2, COVID-19, ddc:610, Kieler Woche, 610 Medizin und Gesundheit, belegbare Betten, Großveranstaltung
Abstract

Im Juni 2022 fand die Kieler Woche ohne pandemiebedingte einschränkende Maßnahmen statt. Im Anschluss daran verdreifachte sich binnen weniger Tage die lokale Sieben-Tage-Inzidenz der SARS-CoV-2-Infektionen. Im selben Zeitraum war bei den COVID-19-bedingten Hospitalisierungen, schweren Erkrankungen und Todesfällen allenfalls ein schwacher Anstieg zu verzeichnen. Dagegen kam es aufgrund der Absonderungsmaßnahmen zu umfangreichen Personalausfällen unter anderem in Krankenhäusern sowie damit auch zu einem starken Rückgang der Anzahl der belegbaren Krankenhausbetten auf Normalstationen. Der Erfahrungsbericht fasst die verfügbaren, quantifizierbaren epidemiologischen Auswirkungen der Kieler Woche 2022 zusammen.

Published
2022

2. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children

Author

Kissling, Esther, Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, van der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, I-MOVE/I-MOVE+ study team, EpiConcept [Paris], National Centre for Microbiology [Madrid], Instituto de Salud Carlos III [Madrid] (ISC), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), Department for Infectious Disease Epidemiology [Berlin], Robert Koch Institute [Berlin] (RKI), Department of Infectious Diseases [Rome, Italy], Istituto Superiore di Sanita, CIBER de Epidemiología y Salud Pública (CIBERESP), National Centre for Epidemiology. CIBERNED. Carlos III Institute of Health, Madrid, Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III [Madrid] (ISC)-Instituto de Salud Carlos III [Madrid] (ISC), National Centre for Epidemiology [Budapest], Public Health Agency of Sweden, Health Protection Surveillance Centre (HPSC), National Institute of Public Health - National Institute of Hygiene [Poland], National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Croatian Institute of Public Health [Zagreb] (CIPH), Génétique moléculaire des virus à ARN ((U-Pasteur_ 2 / UMR_3569)), Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), National Reference Centre for Influenza [Berlin], European Centre for Disease Prevention and Control (ECDC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Istituto Superiore di Sanità (ISS), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), Instituto de Salud Carlos III (ISC), CIBER de Enfermedades Neurodegenerativas (CIBERNED), National Institute of Public Health – National Institute of Hygiene [Varsovie], Instituto Nacional de Saúde Doutor Ricardo Jorge [Lisboa], European Centre for Disease Prevention and Control, Kissling, Esther, Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, van der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, and D'Agaro, Pierlanfranco

Subjects
Male, 0301 basic medicine, Epidemiology, viruses, Influenza B viru, vaccine effectivene, Efetividade da Vacina Antigripal, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, Influenza A Virus, Medicine, 030212 general & internal medicine, Child, Vaccine effectiveness, I-MOVE+, virus diseases, Middle Aged, multicentre study, 3. Good health, Europe, Infectious Diseases, Influenza Vaccines, Child, Preschool, Original Article, Female, Case-Control Studie, influenza, Human, Adult, Pulmonary and Respiratory Medicine, Trivalent influenza vaccine, Lineage (genetic), Adolescent, Influenza vaccine, case-control study, 030106 microbiology, Influenza season, Young Adult, 03 medical and health sciences, Influenza, Human, Humans, I-MOVE, H1N1 Subtype, Vacina Antigripal, ddc:610, Preschool, Aged, vaccine effectiveness, case‐control study, business.industry, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Case-control study, Infant, Influenza a, Original Articles, influenza vaccine, Case-Control Studies, Influenza B virus, Case Control Study, Virology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, vaccine effe, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, 610 Medizin und Gesundheit, business
Abstract

BACKGROUND: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. METHODS: We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. RESULTS: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: -38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: -4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was -47.6% (95% CI: -124.9 to 3.1), 27.3% (95% CI: -4.6 to 49.4) and 9.3% (95% CI: -44.1 to 42.9), respectively. CONCLUSIONS: Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine. ECDC has contributed fund for the coordination and some study sites under the Framework contract no. ECDC/2014/026 for the individuals aged less than 65 years. The I‐MOVE/I‐MOVE+ study team is very grateful to all patients, general practitioners, paediatricians, hospital teams, laboratory teams and regional epidemiologists who have contributed to the study. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID's EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID website http://www.gisaid.org. Sí

Published
2018
Full Text
View/download PDF

3. Vollständigkeit der Tuberkulose-Meldungen in Deutschland in den Jahren 2013 – 2017: Ergebnisse einer Inventurstudie

Author

Domaszewska, Teresa, Karo, Basel, Preuß, Ute, Kollan, Christian, Reuss, Annicka, Blank, Hans-Peter, Brodhun, Bonita, Hauer, Barbara, Altmann, Doris, Fiebig, Lena, Haas, Walter, and Perumal, Nita

Subjects
Surveillance, Meldesystem, Untererfassung, ddc:610, Inventarstudie, 610 Medizin und Gesundheit, Tuberkulose
Abstract

Für die Evaluation der Qualität von Tuberkulose-Meldesystemen ist die Bewertung der Vollständigkeit der Meldedaten von zentraler Bedeutung, da diese die Basis für eine aussagekräftige Tuberkulose-Surveillance und daraus abgeleitete Maßnahmen sind. Wie das Epidemiologische Bulletin 11/2021 beschreibt, wurde am Robert-Koch-Institut für den Zeitraum 2013-17 eine Inventarstudie zur Schätzung der Tuberkulose-Untererfassung in Deutschland durchgeführt. Das Ergebnis: mit einer Erfassungsquote von über 90% ist die Tuberkulose-Melderate trotz eines leichten Rückgangs innerhalb des untersuchten Zeitraums ein guter Näherungswert für die tatsächliche Tuberkulose-Inzidenz.

Published
2021
Full Text
View/download PDF

4. Einfluss der COVID-19-Pandemie auf die Anzahl der gemäß IfSG meldepflichtigen Nachweise von Erregern mit Antibiotikaresistenzen und C. difficile-Infektionen

Author

Reuss, Annicka, Klingeberg, Anja, Schmidt, Nicole, Eckmanns, Tim, and Zacher, Benedikt

Subjects
Antibiotikaresistenz, COVID-19, ddc:610, MRSA, C. difficile, Meldedaten, 610 Medizin und Gesundheit
Abstract

Die vorgestellte Analyse untersucht, inwiefern sich die Meldungen von Erregern mit Antibiotikaresistenzen und C. difficile-Infektionen gemäß IfSG seit Inkrafttreten der Maßnahmen zur Eindämmung der COVID-19-Pandemie verändert haben. Beobachtet wurde ein Rückgang der übermittelten Fallzahlen von Methicillin-resistenten Staphylococcus Aureus (MRSA), C. difficile, Acinetobacter spp. (CRA) und Enterobacterales (CRE). Welche Faktoren genau für diesen Rückgang verantwortlich sind und ob die COVID-19-Pandemie langfristig die Antibiotikaresistenz eher steigert oder verringert bleibt zu untersuchen.

Published
2021

5. Labor-basierte Surveillance SARS-CoV-2

Author

Hoffmann, Alexandra, Noll, Ines, Willrich, Niklas, Reuss, Annicka, Feig, Marcel, Schneider, Marc J., Eckmanns, Tim, Hamouda, Osamah, and Abu Sin, Muna

Subjects
Diagnostik, Surveillance, SARS-CoV-2, Testkapazität, ddc:610, 610 Medizin und Gesundheit, ARS
Abstract

Die 2008 etablierte Antibiotika-Resistenz-Surveillance (ARS) wurde für die Surveillance von SARS-CoV-2 erweitert. Über ARS werden Daten zu jedem einzelnen durchgeführten Test an das RKI übermittelt. Es werden Daten zur virologischen Diagnostik zu SARS-CoV-2 tagesaktuell elektronisch übermittelt. Die besondere Wertigkeit der laborbasierten Surveillance zu SARS-CoV-2 besteht darin, dass über ein etabliertes Surveillancesystem alle in der Routine durchgeführten Testungen erfasst werden, d. h. auch negative Befunde, und damit eine Aussage zum Umfang der in den teilnehmenden Laboren durchgeführten Diagnostik gemacht werden kann.

Published
2020

6. Eigenschaften, Häufigkeit und Verbreitung von Vancomycin-resistenten Enterokokken in Deutschland

Author

Klare, Ingo, Bender, Jennifer K., Werner, Guido, Marktwart, Robby, Reuss, Annicka, Sin, Muna Abu, and Eckmanns, Tim

Subjects
Enterokokken, VRE, Antibiotikaresistenz, Typisierung, Nationales Referenzzentrum, ddc:610, 610 Medizin und Gesundheit
Abstract

Vancomycin-resistente Enterokokken gehören zu den in Deutschland gemäß § 23 Abs. 4 zu erfassenden Erregern und werden mittlerweile in vielen Kliniken in Deutschland häufig beobachtet. Weiterhin weniger klar ist Umfang und Art des klinischen Problems, das sich hinter dieser Beobachtung verbirgt. Der vermehrte Nachweis in den Einrichtungen ist auch am Nationalen Referenzzentrum für Staphylokokken und Enterokokken zu bemerken, wie z. B. an (i) steigenden Einsendezahlen seit 2015 und (ii) einem hohen Bedarf an Typisierungen; letzteres ist nahezu gleichbedeutend mit einem Verdacht auf Transmissionen/Cluster von Infektionen und Besiedlungen in betroffenen Einrichtungen („Ausbrüche“). In den Einsendungen an das NRZ wird zudem, wie im Epidemiologischen Bulletin 35/2019 ausgeführt wird, ein Anstieg an Isolaten mit Resistenzen gegen Reserveantibiotika, dabei vor allem Isolate mit Linezolid-Resistenz, z. T. auch aus lokalen Häufungen, beobachtet.

Published
2019

7. Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I‐MOVE multicentre test‐negative case‐control study, 2011/2012‐2016/2017

Author

Valenciano, Marta, Kissling, Esther, Larrauri, Amparo, Nunes, Baltazar, Pitigoi, Daniela, O'Donnell, Joan, Reuss, Annicka, Horváth, Judit Krisztina, Paradowska-Stankiewicz, Iwona, Rizzo, Caterina, Falchi, Alessandra, Daviaud, Isabelle, Brytting, Mia, Meijer, Adam, Kaic, Bernard, Gherasim, Alin, Machado, Ausenda, Ivanciuc, Alina, Domegan, Lisa, Schweiger, Brunhilde, Ferenczi, Annamária, Korczyńska, Monika, Bella, Antonino, Vilcu, Ana-Maria, Mosnier, Anne, Zakikhany, Katherina, de Lange, Marit, Kurečić Filipovićović, Sanja, Johansen, Kari, and Moren, Alain

Subjects
vaccine effectiveness, case-control study, virus diseases, ddc:610, influenza vaccine, influenza, 610 Medizin und Gesundheit, multicentre study
Abstract

Background Results of previous influenza vaccination effects on current season influenza vaccine effectiveness (VE) are inconsistent. Objectives To explore previous influenza vaccination effects on current season VE among population targeted for vaccination. Methods We used 2011/2012 to 2016/2017 I‐MOVE primary care multicentre test‐negative data. For each season, we compared current season adjusted VE (aVE) between individuals vaccinated and unvaccinated in previous season. Using unvaccinated in both seasons as a reference, we then compared aVE between vaccinated in both seasons, current only, and previous only. Results We included 941, 2645 and 959 influenza‐like illness patients positive for influenza A(H1N1)pdm09, A(H3N2) and B, respectively, and 5532 controls. In 2011/2012, 2014/2015 and 2016/2017, A(H3N2) aVE point estimates among those vaccinated in previous season were −68%, −21% and −19%, respectively; among unvaccinated in previous season, these were 33%, 48% and 46%, respectively (aVE not computable for influenza A(H1N1)pdm09 and B). Compared to current season vaccination only, VE for both seasons' vaccination was (i) similar in two of four seasons for A(H3N2) (absolute difference [ad] 6% and 8%); (ii) lower in three of four seasons for influenza A(H1N1)pdm09 (ad 18%, 26% and 29%), in two seasons for influenza A(H3N2) (ad 27% and 39%) and in two of three seasons for influenza B (ad 26% and 37%); (iii) higher in one season for influenza A(H1N1)pdm09 (ad 20%) and influenza B (ad 24%). Conclusions We did not identify any pattern of previous influenza vaccination effect. Prospective cohort studies documenting influenza infections, vaccinations and vaccine types are needed to understand previous influenza vaccinations' effects.

Published
2018

8. 2015/16 I‐MOVE/I‐MOVE+ multicentre case‐control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage‐mismatched influenza B among children

Author

Kissling, Esther, Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, Van Der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, and I-MOVE/I-MOVE+ Study Team

Subjects
case-control study, virus diseases, vaccine effe, influenza vaccine, influenza, 610 Medizin und Gesundheit, multicentre study, 3. Good health
Abstract

Background During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. Methods We used the test‐negative design in a multicentre case‐control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza‐like illness (ILI) laboratory‐confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza‐positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. Results We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5‐46.7). Among those aged 0‐14, 15‐64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: −32.3 to 65.0), 41.4% (95% CI: 20.5‐56.7) and 13.2% (95% CI: −38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: −4.1 to 56.7). Among those aged 0‐14, 15‐64 and ≥65 years, VE against influenza B was −47.6% (95% CI: −124.9 to 3.1), 27.3% (95% CI: −4.6 to 49.4) and 9.3% (95% CI: −44.1 to 42.9), respectively. Conclusions Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine.

Catalog

Books, media, physical & digital resources
See catalog results